X4 Pharmaceuticals Completes Merger with Arsanis
– Newly Nasdaq-listed XFOR focused on the development of novel therapeutics for the treatment of rare diseases –
“We are very pleased to complete this transformative event that enables
us to achieve the next level of corporate growth as we seek to usher in
a new generation of therapies for patients with rare genetic diseases
and rare cancers. The merger enables us to accelerate our lead program
with X4P-001 in WHIM syndrome towards Phase 3 as we evolve into a
pre-commercial global corporation,” said
The holders of shares of X4 capital stock outstanding immediately prior
to the merger received 0.5702 shares of
Following the merger and the reverse stock split, the combined organization is expected to have approximately 6.7 million shares outstanding.
In connection with the merger,
The combined organization will operate under the leadership of X4’s
management team prior to the merger, including
About WHIM Syndrome
WHIM syndrome is a primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene resulting in susceptibility to certain types of infections. WHIM is an abbreviation for the characteristic clinical symptoms of the syndrome: Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. There is no approved therapy for the treatment of WHIM syndrome.
About
Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statement of historical facts, included in this press release regarding
our strategy, future operations, and plans are forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to the development, potential benefits and uses of
and markets for X4’s product candidates, including X4P-001 and
anticipated clinical trials, including timing and potential results, the
potential benefits of the merger, our evolution into a pre-commercial
global corporation, and our intention to establish a Center of Research
Excellence and its potential benefits. Actual results or events could
differ materially from the plans, intentions, expectations and
projections disclosed in the forward-looking statements. Various
important factors could cause actual results or events to differ
materially from the forward-looking statements that X4 makes, including,
but not limited to, the risk that trials and studies may be delayed and
may not have satisfactory outcomes, potential adverse effects arising
from the testing or use of X4P-001 or other product candidates, the risk
that costs required to develop X4P-001 or other product candidates or to
expand our operations will be higher than anticipated and other risks
described in the “Risk Factors” section of the Registration Statement on
Form S-4 filed by
View source version on businesswire.com: https://www.businesswire.com/news/home/20190313005525/en/
Source:
Investors:
Stephanie Carrington
Westwicke, an ICR
company
646-277-1282
Stephanie.Carrington@icrinc.com
Media:
Darcie
Robinson
Westwicke, an ICR company
203-919-7905
Darcie.robinson@icrinc.com